Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
NCT02919059
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
159
Enrollment
OTHER
Sponsor class
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:
Dapagliflozin 10 mg
DRUG:
Glimepiride 4 mg
Sponsor
IInstituto Gallego de Medicina Vascular